Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04964960 · ClinicalTrials.gov registry record · Phase 2
Pembro+Chemo in Brain Mets
A Phase 2 study, sponsored by John L. Villano, MD, PhD.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT04964960 is a Phase 2 study that was terminated before completion, run by John L. Villano, MD, PhD. The registered enrollment target is 3 participants.
The verdict
NCT04964960, a Phase 2 study, was terminated before completion, sponsored by John L. Villano, MD, PhD.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
The goal of this study is to evaluate whether providing Pembrolizumab prolongs survival and preserves quality of life while minimizing side effects for patients with NSCLC with untreated asymptomatic brain metastasis.
Interventions
- DRUG Pembrolizumab
- DRUG Carboplatin
- DRUG Pemetrexed
- DRUG Paclitaxel
- DRUG Nab paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2022-05-19 |
| Est. Completion | 2023-12-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04964960
The ClinicalTrials.gov registry entry for NCT04964960 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is John L. Villano, MD, PhD, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT04964960 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04964960 about?
NCT04964960 is a clinical study titled "Pembro+Chemo in Brain Mets". The goal of this study is to evaluate whether providing Pembrolizumab prolongs survival and preserves quality of life while minimizing side effects for patients with NSCLC with untreated asymptomatic brain metastasis.
What is the current status of trial NCT04964960?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2022-05-19. Estimated completion is 2023-12-19.
What interventions are being tested in trial NCT04964960?
The interventions under investigation include: Pembrolizumab (DRUG), Carboplatin (DRUG), Pemetrexed (DRUG), Paclitaxel (DRUG), Nab paclitaxel (DRUG).
Who is sponsoring clinical trial NCT04964960?
This trial is sponsored by John L. Villano, MD, PhD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.